Plasma melatonin profi le abnormalities have been described in patients with cirrhosis and generally attributed to impaired hepatic melatonin metabolism. The possibility that they might refl ect circadian clock dysfunction has not been explored. In addition, the relationship between plasma melatonin profi les and the sleep disturbances observed in these patients remains unclear. The aims of this study were: (i) to evaluate circadian clock function and hepatic melatonin metabolism in cirrhotic patients, and (ii) to study the relationship between plasma melatonin profi les and sleep -wake behavior.
INTRODUCTION
The master circadian clock, which is located in the suprachiasmatic nuclei (SCN) of the hypothalamus, regulates sleep timing and other 24 h, or circadian , behavioral, physiological, and biochemical rhythms. The average, endogenous circadian period is approximately 24.18 h ( 1 ) and must be synchronized constantly to the 24 h day by external influences. Light is the major external time cue and reaches the SCN by afferent projections from the retina. The SCN projects, in turn, to the pineal gland, regulating the production of melatonin, which can be thought of as the " neuroendocrine transducer " of the light -dark cycle. Thus, in healthy individuals, plasma melatonin levels are high during night sleep and low during the wakeful hours of the day. Nighttime exposure to bright light causes an acute suppression of pineal melatonin synthesis ( 2 ) ; this effect is used to assess the integrity of the retinal -SCNpineal pathway ( 3 ) . Melatonin is hydroxylated / sulfated to 6-sulfatoxymelatonin (aMT6s), primarily in the liver ( 4 ); aMT6s is subsequently excreted in the urine, in which its profile mirrors that of plasma melatonin ( 5 ) .
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Sleep -wake disturbances are common in patients with cirrhosis ( 6 -8 ) but the pathophysiology remains unknown. As melatonin is metabolized in the liver, it has been hypothesized that circadian sleep regulation might be implicated. Indeed, certain reported abnormalities, including high daytime plasma melatonin concentrations ( 9, 10 ) , low urinary aMT6s concentrations (11) , and a reduction in the clearance of exogenously administered melatonin ( 12 ) , support this hypothesis. However, other reported abnormalities, for example, delays in the nocturnal rise of plasma melatonin and in its time to peak ( 9, 13 ) , cannot be explained by impairment of hepatic metabolism but might indicate a dysfunction of the central circadian clock, and hence circadian timing.
Th e primary aim of this study was to determine the etiology of the abnormalities of the plasma melatonin profi le observed in patients with cirrhosis and, specifi cally, to assess the role of:
1. Central circadian output, by: (i) a simultaneous assessment of the 24 h rhythm of two reliable markers of the hypothalamic clock phase, i.e., plasma melatonin / cortisol; and (ii) measurement of the plasma melatonin response to nocturnal administration of bright light.
2. Hepatic melatonin metabolism, by: (i) comparing the plasma melatonin and urinary aMT6s 24 h profi les; and (ii) measuring plasma melatonin clearance.
Th e secondary aim was to assess the contribution of circadian regulation to the sleep -wake abnormalities observed in this patient population.
METHODS

Study subjects
Th e patient population comprised 20 consecutively enrolled individuals of mean (range) age 59 (39 -77) years, with biopsyproven cirrhosis, which was alcohol-related in the majority. Th e functional severity of the liver injury was assessed using Pugh ' s modifi cation of the Child grading system ( 14 ) . Patients were further classifi ed as having compensated (Pugh ' s score ≤ 7; n = 15) or decompensated (Pugh ' s score > 7; n = 5) disease. Patients were excluded from the study if they had misused alcohol in the preceding 6 months, had an estimated glomerular fi ltration rate of < 80 ml / min, a history of insulin-dependent diabetes mellitus, signifi cant head injury, cardio-or cerebrovascular disease, signifi cant neurological / psychiatric comorbidity, or corrected visual acuity of less than 6 / 6; if they were taking neuroactive medication / medication known to aff ect sleep and / or melatonin production, had traveled across more than two time zones in the preceding 3 months or undertaken shift work in the preceding 5 years, or were not suffi ciently robust to undergo the study procedures.
Th e reference population comprised 9 healthy volunteers of mean age 60 (38 -84) years. None drank alcohol in excess of 20 g / day, had corrected visual acuity of less than 6 / 6, were taking prescription medication, or had traveled or undertaken shift work as defi ned above.
Study design
Individual studies were conducted over a 15-day period, in three separate locations, namely, the Royal Free Hospital, London (clinical evaluation, sleep questionnaire), the patients ' homes (sleep diaries, actigraphy, and screening urinary aMT6s profi le), and the Clinical Investigations Unit of the University of Surrey (plasma melatonin / cortisol profi les, urinary aMT6s profi le, plasma melatonin response to light) ( Table 1 ) .
Subjects were asked to refrain from taking caff einated / alcoholcontaining beverages and to avoid strenuous exercise and ex posure to bright natural light from day 12 onwards. Controls were exercised for both light and posture during the time spent in the Clinical Investigations Unit ( Table 2 ). A maximum of three subjects were studied at any one time to allow close surveillance and to ensure compliance with study procedures.
Sleep -wake profi le (days 1 -12)
Subjective sleep quality (day 1): Subjects were asked to complete the Pittsburgh Sleep Quality Index (PSQI) ( 15 ) . Th is is a self-administered questionnaire and is used to assess subjective sleep quality over the preceding month; total PSQI scores of > 5 (range 0 -21) identify " poor " sleepers ( 15 ) . Sleep diaries: Subjects kept individual daily sleep diaries for 12 consecutive days, in which they recorded their bedtime , the time they started trying to sleep , their sleep onset , wake-up and get-up times , and the number of naps they took during the following day ( 16 ).
• • ( 17 ) .
Urinary aMT6s profi le (days 1 -3, 13 -14)
Two separate urine collections were undertaken:
Days 1 -3: to determine the timing for light exposure ( vide infra ) ; Days 13 -14: to determine plasma melatonin clearance.
Sequential urine samples were collected at 4 h intervals during the day and at 8 h intervals overnight. Aliquots of 3 ml were extracted from each individual collection and kept at − 20 ° C until assayed for aMT6s, using a radioimmunoassay ( 18 ) . Th e intra-assay coeffi cients of variation (CVs) ranged from 10 % to 11 % , the inter-assay CV ranged from 6 % to 12 % , and the limit of detection was 0.3 ng / ml. Th e total 24-h urinary aMT6s output was obtained. Th e urinary aMT6s profi le was evaluated using cosinor analysis, which is based on the least square approximation of the time series using a cosine function with a period of 24 h ( 19 ) . If the function fi ts the time series, the latter is deemed to have a sinusoidal 24 h rhythm, and a number of socalled " cosinor " parameters can be reliably obtained. Data were accepted if the probability of the cosinor fi t ( P ) was < 0.05 ( 19 ) . Th e circadian parameter, acrophase time -maximum of the fi tted cosinor function or time of the peak urinary aMT6s concentration -was obtained, and classed as delayed if it occurred aft er 06:00 ( 20 ) , regardless of sleep -wake timing.
Plasma melatonin and cortisol profi les (days 13 -14)
Venous blood samples for measurement of plasma melatonin / cortisol concentrations were obtained hourly between 18 : 00 and 10 : 00 and every two hours between 10 : 00 and 18 : 00, on days 13 and 14.
• • • Assays . Plasma melatonin was measured using a radioimmunoassay ( 21 ); the intra-assay CV ranged from 7 % to 14 % , the interassay CV ranged from 9 % to 11 % , and the limit of detection was 2.6 pg / ml. Plasma cortisol was also measured using a radioimmunoassay ( 22 ) ; the intra-assay CV ranged from 5 % to 12 % , the inter-assay CV ranged from 8 % to 15 % , and the limit of detection was 10.5 nmol / l.
Cosinor analysis . Plasma melatonin / cortisol profi les were examined by cosinor analysis ( 19 ) ; data were accepted if the probability of the cosinor fi t ( P ) was < 0.05 for melatonin and < 0.2 for cortisol, because of the more erratic nature of its rhythm ( 23 ) . Th e following parameters were obtained: acrophase time , maximum of the fi tted cosinor function or time of the peak plasma melatonin / cortisol concentration; mesor , average plasma melatonin / cortisol concentration over 24 h; and amplitude , diff erence between mesor and acrophase plasma melatonin / cortisol concentrations.
Onset / Off set analysis . Th e onset and off set of the plasma melatonin and cortisol rhythms were defi ned as the time points, on the rise and fall of the concentration -time curve, when the plasma concentrations equaled 25 % of the peak concentration ( 24 ); these parameters could only be calculated in subjects with a discernable peak on inspection. Th e time interval between the rhythm onset and off set was defi ned as the peak duration .
Melatonin clearance
Th e area under the curve of the plasma melatonin profi le was calculated by integrating point plasma concentrations over the time interval between consecutive samples. Estimates of plasma melatonin clearance (l / kg per h) were obtained, on the basis of the assumption that aMT6s was the only metabolite:
24[average plasma melatonin(pg/m ml)] body weight(kg)] [
where k = aMT6s molecular weight / melatonin molecular weight Th e overnight (23 : 00 -08 : 00) clearance was also calculated, using matched, timed plasma / urine samples.
Sleep -circadian phase
Th e phase relationship between circadian and sleep rhythms was assessed by subtracting the average wake-up time over the 12 monitored days from the plasma melatonin rhythm onset time (reference range: 12.5 -17.1 h ( 25 )).
Light suppression test (day 15)
Th e light administration time was standardized so that individuals were exposed to light during the rising phase of their plasma melatonin rhythm; this was assumed to occur 2.5 -4.5 h before the urinary aMT6s acrophase, estimated using the urine collections performed on days 1 -3 ( 26 ) .
Pupils were dilated using 0.5 % topical tropicamide. Subjects sat in front of a light sphere (45 cm diameter, Apollo Lighting) for 30 min, with their head on a chin rest; they kept their eyes open and LIVER looked straight ahead ( 27 ) . White light (4.1 * 10 14 photons / cm 2 per second) was generated by a metal halide arc lamp source (Enlightened Technology Associates, Fairfax, VA) and delivered through a fi ber-optic bundle ( 27 ) . Blood was taken every 15 min for 90 min from the beginning of light administration.
Maximal melatonin suppression was defi ned as the percentage decrease in plasma melatonin concentration aft er 30 min of light exposure ( 27 ) . An average of the point suppression values was also calculated; individuals with negative averages were classed as showing no response.
Statistical analysis
Data are presented as mean ± s.d. or s.e.m. (range). Th e distribution of variables was tested for normality using the Shapiro -Wilk ' s W -test. Diff erences between normally / nonnormally distributed variables were examined using Student ' s t -test / Mann -Whitney Utest. Categorized indices were compared by the Maximum Likelihood χ 2 -test or Fisher ' s exact test, as appropriate. Correlations between indices were tested using Spearman ' s R .
Ethics
Th e study was conducted according to the Declaration of Helsinki Principles (Hong Kong Amendment) and Good Clinical Practice (European Guidelines). Th e protocol was approved by the Royal Free Hampstead NHS Trust Ethics Committee and by the University of Surrey Ethics Committee. All participating subjects provided written, informed consent.
RESULTS
Subject characteristics and sleep behavior
Of the 20 patients enrolled, 14 (70 % ) were classed as Child ' s grade A, 4 (20 % ) as grade B, and 2 (10 % ) as grade C; of these, 15 (75 % ) were further classifi ed as having compensated and 5 (25 % ) as having decompensated disease. Both patients and healthy volunteers had similar age and gender distributions ( Table 3 ).
Sleep quality was generally impaired in patients compared with healthy volunteers (PSQI abnormal: 70 % vs. 33 % , P = 0.07; acti graphy night activity: 11380 ± 12089 vs. 5509 ± 2025 counts, P = 0.07; actigraphy fragmentation index: 41 ± 19 vs. 32 ± 7, P = 0.08); the mean actigraphy immobile time was signifi cantly decreased (79 % ± 11 % vs. 86 % ± 3 % , P = 0.04) ( Table 3 ). Sleep timing was generally delayed in patients; the mean wake-up time was signifi cantly delayed (07 : 42 ± 02 : 00 vs. 06 : 36 ± 00 : 54 P = 0.03) ( Table 3 ) .
Circadian profi les in healthy volunteers and patients with cirrhosis
Urinary aMT6s . Cosinor analysis showed an acceptable fi t in all subjects. Th e mean urinary aMT6s acrophase was delayed by approximately 1.5 h in patients compared with healthy volunteers, but the diff erence was not signifi cant (05:12 ± 02:24 vs. 03:48 ± 01:30; P = 0.13). Th e urinary aMT6s acrophase was abnormally delayed (aft er 06:00) in eight (40 % ) patients but in none of the healthy volunteers ( P = 0.007).
Plasma melatonin . Cosinor analysis showed a signifi cant fi t in 7 (78 % ) healthy volunteers and in 19 (95 % ) patients; onset / off set analysis was possible in 7 (78 % ) healthy volunteers and in 18 (90 % ) patients. Th ere were no signifi cant diff erences in plasma melatonin mesor or amplitude between patients and healthy volunteers ( Table 4 ) . Th e plasma melatonin rhythm was delayed in patients compared with healthy volunteers, the delay aff ecting the rhythm onset ( P = 0.09), its acrophase ( P = 0.01), and its off set ( P = 0.08) ( Table 4 , Figure 1 ). No signifi cant diff erences were observed in peak duration.
Patients with decompensated cirrhosis showed delays in plasma melatonin rhythm onset (24:21 ± 02:12 vs. 22:29 ± 01:14, P = 0.08) and in urinary aMT6s acrophase time (06:45 ± 01:49 vs. 04:45 ± 02:26, P = 0.07), compared with their compensated counterparts; in addition, they had a signifi cantly higher plasma melatonin mesor (47.5 ± 15.3 vs. 31.2 ± 20.6 pg / ml, P = 0.05).
Signifi cant correlations were observed between plasma melatonin rhythm parameters and stand-alone / composite indices of hepatic dysfunction ( Table 5 ).
Plasma cortisol . Cosinor analysis showed an acceptable fi t in 8 (89 % ) healthy volunteers and in 18 (90 % ) patients. Onset / off set analysis could be performed in all subjects; however, in 2 (22 % ) healthy volunteers and 7 (35 % ) patients, the plasma cortisol rhythm off set occurred aft er 18 : 00, beyond sampling time, 
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between patients and healthy volunteers ( Table 4 ) ; the duration of the peak was signifi cantly shorter in the 13 patients compared with the 7 healthy volunteers in whom this parameter was obtained ( Table 4 ) . No signifi cant diff erences in plasma cortisol rhythm parameters were observed between patients with compensated and decompensated cirrhosis. However, a signifi cant correlation was thus the parameters off set and duration could not be obtained. Th ere were no signifi cant diff erences in plasma cortisol mesor or amplitude between patients and healthy volunteers ( Table 4 ) . Th e plasma cortisol rhythm was delayed in patients compared with healthy volunteers, the delay aff ecting the rhythm onset ( P = 0.02) and its acrophase ( P = 0.06) ( Table 4 ) . No signifi cant difference was observed in the timing of the rhythm offset Signifi cance of the differences between healthy volunteers and patients with cirrhosis: (a) 0.05 < P < 0.1; a P < 0.05. Acrophase: maximum of the fi tted cosinor function, or time of the peak concentration; Mesor: average concentration over the 24 h; Amplitude: difference between the mesor and the acrophase concentrations; Onset / offset: time points, on the rise and fall of the concentration -time curve, when the plasma concentrations equaled 25 % of the peak concentration; Duration : time interval between the rhythm onset and offset. Montagnese et al.
observed between plasma cortisol acrophase time and the Pugh ' s score ( R = 0.49, P < 0.05).
Light suppression . Th e time course of the mean plasma mel atonin suppression profi le of patients and healthy volunteers was similar, with minimal plasma melatonin levels (maximal suppression) 30 min aft er the beginning of light administration. How ever, patients showed a blunted, though not signifi cantly diff erent, maximal plasma melatonin response (12 % ± 19 % vs. 24 % ± 15 % , P = 0.09; Figure 2 ); four patients showed no light response at all (23 % vs. 0 % , P = 0.03).
Relationships between circadian variables . No signifi cant diff erences were observed between patients and healthy volunteers in the time interval between plasma melatonin and the urinary aMT6s acrophase (1.3 ± 1.8 vs. 1.6 ± 0.8 h, P > 0.05), the area under the curve of the plasma melatonin profi le, or the 24-h plasma melatonin clearance. However, patients showed a signifi cantly reduced overnight plasma melatonin clearance (0.11 ± 0.06 vs. 0.21 ± 0.13 l / kg per h, P = 0.02). A signifi cant correlation was observed between the plasma melatonin and plasma cortisol acrophase times ( R = 0.46, P < 0.05). Finally, signifi cant negative correlations were observed between plasma melatonin / cortisol acrophase times and the maximal suppression at 30 min from the beginning of light administration ( R = − 0.46; R = − 0.43, P < 0.05; Figure 3 ).
Circadian profi les and sleep behavior
No signifi cant diff erences in plasma melatonin profi le indices were observed between subjects classifi ed as " good " or " poor sleepers " on the basis of the PSQI score. Similarly, no signifi cant correlations were observed between plasma melatonin profi le and actigraphic indices.
A signifi cant correlation was observed between the plasma melatonin rhythm onset time and habitual wake-up time in healthy volunteers, but not in patients with cirrhosis, in whom these parameters showed greater variability ( Figure 4 ). Four (22 % ) patients with cirrhosis had a phase relationship that was either shorter ( n = 1) or longer ( n = 3) than the reference range, a feature not observed in healthy volunteers ( Figure 4 ).
DISCUSSION
Patients with cirrhosis exhibited delays in both plasma mel atonin and cortisol 24 h rhythms and a reduction in their plasma melatonin response to light. Th ese changes indicate the presence of central circadian disruption. In contrast, there was limited Healthy volunteers (n=9) * Figure 2 . Mean ( ± s.e.m.) plasma melatonin suppression, 15 -90 min after the beginning of light administration in healthy volunteers and in patients with cirrhosis. The response profi le was similar in the two groups, with minimal plasma melatonin levels (maximal suppression) at 30 min from the beginning of light administration; however, patients showed an attenuated plasma melatonin response to light at all times. * P = 0.09.
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comparable in patients and healthy volunteers and no diff erences were observed in the average area under the curve of the plasma melatonin profi le or in the 24 h melatonin clearance. Interestingly, overnight plasma melatonin clearance was reduced, probably indicating that some degree of impairment in hepatic disposition does exist in these patients but is only apparent when plasma melatonin concentrations are high. Th is hypothesis is supported by the signifi cant positive correlations observed between indices evidence of impaired hepatic melatonin metabolism. Patients with cirrhosis also showed a degree of misalignment between sleep and circadian timing, but there was no obvious association between circadian abnormalities and impaired sleep quality.
Melatonin metabolism
Th e duration of the plasma melatonin peak and the time interval between plasma melatonin and urinary aMT6s peaks were Figure 3 . Correlation between plasma melatonin suppression at 30 min from the beginning of light administration and plasma melatonin acrophase time in healthy volunteers and in patients with cirrhosis. The gray shade highlights a substantially " normal " area, in which suppression is > 15 % and the acrophase occurs before 05:00. In general, patients with a delayed plasma melatonin acrophase time also had poor plasma melatonin responses to light (red squares outside the gray-shaded area). Healthy volunteers (n =7)
Patients with cirrhosis (n =18) Figure 4 . Relationship between the plasma melatonin rhythm onset time and habitual wake-up times in healthy volunteers (left) and in patients with cirrhosis (right). The correlation between the two parameters was signifi cant in healthy volunteers but not in patients. Four patients had a phase relationship that was either shorter (square) or longer (circles) than the reference 12.5 -17.1 h range ( 25 ) .
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of increasing hepatic dysfunction and increases in the plasma melatonin mesor -the average concentration over 24 h -and delays in the off set of the plasma melatonin rhythm. Th us, these data, which were obtained in patients with mild to moderately decompensated liver disease, would seem to indicate that the overall contribution of impaired hepatic metabolism to the disruption in the plasma melatonin profi le in patients with cirrhosis is small. However, the eff ect may be more signifi cant, and hence more evident, in patients with more severe decompensation. Th e demands of this study were such that individuals with end-stage liver disease could not be included.
Th ere are few, if any, published studies with which to compare these data. Steindl et al. ( 11 ) , reported a reduction in urinary aMT6s output in 21 patients with cirrhosis, which they interpreted as showing an impairment in hepatic melatonin catabolism, yet were unable to show any relationship between urinary MT6s concentrations and various indices of hepatic function. However, their observations were based on measurement of urinary aMT6s in a single, 8 h overnight urine collection, which, as such, will not have provided representative data.
Circadian clock output
Signifi cant delays were observed in the rising phase of the plasma melatonin profi le in patients with cirrhosis, resulting in an overall shift of the 24 h rhythm towards a later hour. Th e shift was more pronounced in patients with decompensated disease. Th ese fi ndings are substantially in line with those of Steindl et al. ( 9 ) , who originally hypothesized that the clock output might be abnormal in this patient population. Th e attenuated melatonin response to light observed in this study provides further and more robust evidence of central circadian disruption.
Signifi cant delays were also observed in the rising phase of the plasma cortisol profi le in patients with cirrhosis. Th ese fi ndings contrast with those of Bernardi et al. ( 28 ) and Velissaris et al. ( 10 ) . However, these studies can be criticized for two reasons: (i) the number of plasma samples obtained for cortisol measurement was smaller than required for accurate estimates of rhythm timing ( 29 ) ; (ii) controls were not exercised for light exposure, which is important, as even ordinary room light has been shown to have phase-resetting eff ects on the cortisol rhythm, mediated through the hypothalamic clock ( 30 ) . Th e reduced duration of the plasma cortisol peak observed in the patients with cirrhosis in this study is diffi cult to interpret. Shortening of plasma cortisol peaks has been reported in healthy volunteers in response to chronic exposure to short nights ( 31 ) . It is possible that chronically interrupted night rest might produce a similar result.
Th e observed delays in plasma melatonin and cortisol rhythms occurred in parallel, providing further evidence for dysfunctional clock output. Piscaglia et al. ( 13 ) obtained plasma melatonin and plasma fi brinolysis function profi les in patients with cirrhosis and in healthy volunteers. Patients showed a delay in the plasma melatonin acrophase but not in that of fi brinolysis indices, leading the authors to conclude that circadian clock function is preserved in this patient population ( 13 ) . Th e choice of plasma fi brinolysis as a circadian marker is questionable because the nature of plasma fi brinolysis rhythmicity and, more importantly, its relation to the SCN output are unknown. In contrast, plasma melatonin and plasma cortisol are recognized, direct markers of clock phase ( 32 ) .
Pathophysiology
Th e cause of the retinal -SCN -pineal pathway dysfunction, in patients with cirrhosis, remains unknown, but hypotheses can be formulated. Low-grade swelling has been observed in retinal M ü ller cells in patients with cirrhosis and has been associated with changes in the electroretinogram and in color discrimination ( 33 ) . It is not known whether photoreceptors and retinal ganglion cells are also aff ected but, if so, this might impinge on the process of light entrainment. In this study, delays in the plasma melatonin acrophase were associated with blunted light-induced suppression responses, suggesting that the former might be a consequence of a reduced sensitivity to light. Similar abnormalities have been reported in blind subjects ( 34 ) . Central GABAergic / glutamatergic neurotransmission is also disrupted in patients with cirrhosis ( 35 ) . GABA and glutamate are involved in the transmission of the photic stimulus from the retina to the SCN ( 36 ) . Th us, increased GABAergic tone might disrupt the retinal -SCN pathway and, in consequence, the output of the clock.
Clinical relevance
In this study, patients with cirrhosis showed a degree of misalignment between their sleep and circadian timing. Th e abnormal phasing of internal rhythms relative to one another, especially if long standing, has been shown to have ser ious adverse eff ects on safety, performance, and health. Shift workers, for example, have increased incidences of metabolic syndrome, heart disease, and even cancer ( 37, 38 ) . Th erefore, the long-term eff ects of circadian delays and circadian -sleep misalignment in patients with cirrhosis are certainly worthy of further investigation.
However, there was no obvious association between circadian abnormalities and impaired sleep quality, indicating that the sleep disturbances observed in these patients are unlikely to depend on circadian derangement ( 39 ) . Alternative pathophysiological pathways, in particular, homeostatic sleep regulation, need to be explored.
In conclusion, the plasma melatonin profi le abnormalities exhibited by patients with mild to moderately decompensated cirrhosis are predominantly central in origin, and are substantially unrelated to the sleep disturbances observed in this patient population.
